AQST logo

AQUESTIVE THERAPEUTICS INC

AQSTNASDAQ
πŸ† #2862 by market capEarnings Mar 3US Equity
β€”β€”
Quote unavailable
πŸ””
Track AQST
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$435M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-22.6%
Declining
πŸ“ŠGross Margin
65.3%
High
πŸ’΅FCF Margin
-83.3%
Thin
βš–οΈP/S Ratio
8.9x
Elevated
Otter Score
β€”
Insufficient data
No chart data available for AQST.

Trading Snapshot

Day Range
β€”
52-Week Range
$2.93 – $6.74
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
125.7M
Next Earnings
2027-03-03

Fundamentals Snapshot

Annual Revenue
$45M
Last Q Revenue
$8M
P/E Ratio
-5.4
P/S Ratio
8.9x
EPS (TTM)
$-0.63
Dividend Yield
0.00%
Dilution (1yr)
+33.7%
AQST logo

AQUESTIVE THERAPEUTICS INC

AQST
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$45Mβ–Ό βˆ’22.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.5%β–Ό βˆ’10.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$70Mβ–² +126.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$53Mβ–² +47.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
122.0Mβ–² +33.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$10Mβ–Ό βˆ’$44M YoY
StockOtter Β· stockotter.space

About AQUESTIVE THERAPEUTICS INC

Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·4d ago

Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference

WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' live

MarketBeatΒ·6d ago

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics NASDAQ: AQST is preparing for a potential U.S. launch of its needle-free treatment for severe allergic reactions, with an FDA decision expected on March 16, 2027, CEO Dan Barber said at the 2026 Je

GlobeNewsWireΒ·13d ago

Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference

WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' live

GlobeNewsWireΒ·17d ago

Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting

WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (β€œAquestive” or the β€œCompany”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' liv

Defense WorldΒ·17d ago

Traders Purchase Large Volume of Put Options on Aquestive Therapeutics (NASDAQ:AQST)

Aquestive Therapeutics, Inc. (NASDAQ: AQST - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders purchased 6,009 put options on the company. This is an increase of approx

Seeking AlphaΒ·18d ago

Aquestive Therapeutics, Inc. (AQST) Q3 2026 Earnings Call Transcript

Aquestive Therapeutics, Inc. ( AQST ) Q3 2026 Earnings Call November 4, 2026 8:00 AM EST Company Participants Faith Pomeroy-Ward Daniel Barber - CEO, President & Director Ernie Toth - Senior VP & CFO Sherry Korczynski -